https://www.astrazeneca.ca/en/ 2024-03-13T13:12:18.275Z https://www.astrazeneca.ca/en/search-results.html 2026-02-03T18:49:26.506Z https://www.astrazeneca.ca/en/500.html 2026-01-30T18:21:14.740Z https://www.astrazeneca.ca/en/503.html 2026-01-30T18:21:08.921Z https://www.astrazeneca.ca/en/404.html 2026-01-30T18:20:56.035Z https://www.astrazeneca.ca/en/our-medicines.html 2026-08-07T19:28:16.287Z https://www.astrazeneca.ca/en/our-medicines/focus-areas.html 2026-02-03T18:55:01.266Z https://www.astrazeneca.ca/en/our-medicines/patient-assistance-program.html 2026-02-03T18:55:16.164Z https://www.astrazeneca.ca/en/our-science.html 2026-02-03T18:50:29.081Z https://www.astrazeneca.ca/en/sustainability.html 2026-02-03T18:50:57.784Z https://www.astrazeneca.ca/en/sustainability/improving-access-to-care.html 2026-02-03T18:56:31.875Z https://www.astrazeneca.ca/en/sustainability/science-innovation.html 2026-02-03T18:57:00.243Z https://www.astrazeneca.ca/en/sustainability/requesting-support.html 2026-02-03T18:56:40.793Z https://www.astrazeneca.ca/en/sustainability/exclusionary-criteria.html 2026-02-03T18:57:14.867Z https://www.astrazeneca.ca/en/sustainability/our-community.html 2026-02-03T18:56:16.189Z https://www.astrazeneca.ca/en/sustainability/eureka-fellowship.html 2026-08-05T18:45:12.813Z https://www.astrazeneca.ca/en/sustainability/community-investment-donation-requirements.html 2026-02-03T18:58:49.785Z https://www.astrazeneca.ca/en/sustainability/grant-application-requirements.html 2026-02-03T18:58:42.964Z https://www.astrazeneca.ca/en/sustainability/sponsorships.html 2026-02-03T18:58:35.816Z https://www.astrazeneca.ca/en/sustainability/grants.html 2026-02-03T18:58:24.375Z https://www.astrazeneca.ca/en/sustainability/community-investments-donations.html 2026-02-03T18:59:12.869Z https://www.astrazeneca.ca/en/sustainability/reconciliation-requirements.html 2026-02-03T18:59:22.497Z https://www.astrazeneca.ca/en/media.html 2026-02-03T18:51:17.907Z https://www.astrazeneca.ca/en/media/media-contacts.html 2026-02-03T19:03:31.517Z https://www.astrazeneca.ca/en/media/press-releases.html 2026-02-03T19:03:16.187Z https://www.astrazeneca.ca/en/media/press-releases/2016.html 2026-02-03T19:05:35.119Z https://www.astrazeneca.ca/en/media/press-releases/2016/tagrisso-approved-by-health-canada.html 2016-10-12T20:14:52.040Z https://www.astrazeneca.ca/en/media/press-releases/2016/health-canada-approves-lynparza.html 2016-11-09T17:43:48.834Z https://www.astrazeneca.ca/en/media/press-releases/2016/benralizumab-phase-iii-trials-show-positive-results-in-severe-asthma.html 2016-10-12T20:17:53.622Z https://www.astrazeneca.ca/en/media/press-releases/2016/canada-denies-public-access-to-potentially-life-prolonging-ovarian-cancer-treatment-lynparza.html 2016-10-14T16:52:56.230Z https://www.astrazeneca.ca/en/media/press-releases/2016/lynparzaolaparibphaseiiisolo2trial.html 2016-11-02T12:46:48.598Z https://www.astrazeneca.ca/en/media/press-releases/2016/tagrisso---osimertinib--demonstrates-superiority-over-chemothera.html 2024-02-08T18:12:43.625Z https://www.astrazeneca.ca/en/media/press-releases/2015.html 2026-02-03T19:08:20.577Z https://www.astrazeneca.ca/en/media/press-releases/2015/duaklir-genuair-now-available-in-canada.html 2024-02-08T18:01:32.671Z https://www.astrazeneca.ca/en/media/press-releases/2015/new-flumist-quadrivalent-flu-vaccine.html 2024-02-08T18:02:04.624Z https://www.astrazeneca.ca/en/media/press-releases/2015/astrazeneca-invest-500000-forge-ahead-research-program.html 2024-02-08T18:02:19.111Z https://www.astrazeneca.ca/en/media/press-releases/2015/contextual-genomics-and-the-personalized-initiative-receive-funding-from-astrazeneca.html 2024-02-08T18:02:31.800Z https://www.astrazeneca.ca/en/media/press-releases/2015/pegasus-timi-54-study-of-brilinta-meets-primary-endpoint.html 2024-02-08T18:02:44.341Z https://www.astrazeneca.ca/en/media/press-releases/2014.html 2026-02-03T19:05:47.939Z https://www.astrazeneca.ca/en/media/press-releases/2014/help-keep-flu-away-with-gentle-spray.html 2024-02-08T18:16:27.230Z https://www.astrazeneca.ca/en/media/press-releases/2013.html 2026-02-03T19:05:58.152Z https://www.astrazeneca.ca/en/media/press-releases/2013/collaboration-partnerships-and-a-green-approach-unite-to-create.html 2016-10-12T18:34:13.131Z https://www.astrazeneca.ca/en/media/press-releases/2013/astrazeneca-human-edge-the-ontario-science-centres-new-exhibition-explores-human-body.html 2016-10-12T18:35:23.506Z https://www.astrazeneca.ca/en/media/press-releases/2013/ontario-science-centre-announces-astrazeneca-human-edge.html 2016-10-12T18:21:05.565Z https://www.astrazeneca.ca/en/media/press-releases/2013/real-world-evidence-shows-importance-of-treatment-choice.html 2016-10-18T00:27:19.019Z https://www.astrazeneca.ca/en/media/press-releases/2013/neomed-and-astrazeneca-broaden-strategic-alliance.html 2016-10-12T18:24:29.228Z https://www.astrazeneca.ca/en/media/press-releases/2013/real-world-study-comparing-commonly-prescribed-copd-medicines-shows-choice-of-treatment-has-impact-on-patient-outcomes.html 2016-10-18T00:25:58.245Z https://www.astrazeneca.ca/en/media/press-releases/2013/astrazeneca-donates-225000-to-support-heart-disease-research.html 2016-10-12T18:29:11.192Z https://www.astrazeneca.ca/en/media/press-releases/2013/mood-app-designed-for-youth-by-youth-launches-today.html 2016-10-16T17:53:43.835Z https://www.astrazeneca.ca/en/media/press-releases/2017.html 2026-02-03T19:06:11.600Z https://www.astrazeneca.ca/en/media/press-releases/2017/lynparza---olaparib--phase-iii-solo-2-trial-demonstrates-signifi.html 2017-03-17T16:51:33.378Z https://www.astrazeneca.ca/en/media/press-releases/2017/AstraZenecaSupportsFederalGovernmentsPlanstoGrowCanadasHealthBioSciencesSector.html 2017-03-28T19:37:15.158Z https://www.astrazeneca.ca/en/media/press-releases/2017/astrazeneca-commends-the-ontario-government-on-a-balanced-budget.html 2017-04-28T15:16:53.713Z https://www.astrazeneca.ca/en/media/press-releases/2017/pan-canadian-oncology-drug-review-recommendation-supports-the-us.html 2017-05-08T12:01:23.138Z https://www.astrazeneca.ca/en/media/press-releases/2017/phase-iii-zondatrial-for-benralizumab-shows-ability-to-reduce-or.html 2017-09-12T15:09:01.400Z https://www.astrazeneca.ca/en/media/press-releases/2017/lynparza---olaparib--significantly-reduces-the-risk-of-disease-w.html 2017-06-06T14:56:46.249Z https://www.astrazeneca.ca/en/media/press-releases/2017/astrazeneca-presents-superior-progression-free-survival-for-durv.html 2021-03-02T21:46:52.101Z https://www.astrazeneca.ca/en/media/press-releases/2017/astrazeneca_s-tagrisso-shows-potential-as-a-new-standard-of-care.html 2021-03-02T21:39:16.496Z https://www.astrazeneca.ca/en/media/press-releases/2017/astrazeneca-presents-new-results-identifying-severe-asthma-patie.html 2017-09-12T14:34:50.267Z https://www.astrazeneca.ca/en/media/press-releases/2017/first-in-class-brca-positive-ovarian-cancer-medicine-lynparza---.html 2017-09-21T18:09:31.419Z https://www.astrazeneca.ca/en/media/press-releases/2017/health-canada-approves-imfinzi---durvalumab--for-previously-trea.html 2017-11-06T15:36:15.420Z https://www.astrazeneca.ca/en/media/press-releases/2018.html 2026-02-03T19:06:25.030Z https://www.astrazeneca.ca/en/media/press-releases/2018/tagrisso---osimertinib--receives-full-health-canada-approval-for.html 2018-01-31T16:35:15.441Z https://www.astrazeneca.ca/en/media/press-releases/2018/health-canada-has-approved-fasenra---benralizumab-injection--for.html 2018-02-26T18:31:51.378Z https://www.astrazeneca.ca/en/media/press-releases/2018/first-and-only-immuno-oncology-treatment--imfinzi---durvalumab--.html 2018-05-09T13:21:18.456Z https://www.astrazeneca.ca/en/media/press-releases/2018/lynparza---olaparib--tablets-receive-approval-as-maintenance-the0.html 2018-05-08T15:01:06.965Z https://www.astrazeneca.ca/en/media/press-releases/2018/lynparza---olaparib--receives-new-indication-for-brca-mutated-me.html 2018-05-10T16:40:58.028Z https://www.astrazeneca.ca/en/media/press-releases/2018/health-canada-approves-tagrisso---osimertinib--as-first-line-tre.html 2018-07-12T14:29:19.485Z https://www.astrazeneca.ca/en/media/press-releases/2018/imfinzi---durvalumab--is-the-first-immunotherapy-to-demonstrate-.html 2018-10-26T17:12:08.379Z https://www.astrazeneca.ca/en/media/press-releases/2018/forxiga-significantly-reduced-hospitalisation-for-heart-failure-.html 2018-11-12T20:46:43.054Z https://www.astrazeneca.ca/en/media/press-releases/2019.html 2026-02-03T19:06:38.557Z https://www.astrazeneca.ca/en/media/press-releases/2019/first-and-only-parp-inhibitor--lynparza---olaparib--approved-as-.html 2024-02-08T18:17:26.438Z https://www.astrazeneca.ca/en/media/press-releases/2019/symbicort--turbuhaler--now-approved-by-health-canada-for-mild--p.html 2024-02-08T18:17:41.911Z https://www.astrazeneca.ca/en/media/press-releases/2019/canada-hosts-nobel-prize-inspiration-initiative-for-first-time-.html 2024-02-08T18:17:56.806Z https://www.astrazeneca.ca/en/media/press-releases/2019/health-canada-approves-calquence---acalabrutinib--for-adult-pati.html 2024-02-08T18:18:11.337Z https://www.astrazeneca.ca/en/media/press-releases/2020.html 2026-02-03T19:06:52.614Z https://www.astrazeneca.ca/en/media/press-releases/2020/new-treatment-approved-in-canada-for-most-common-type-of-leukemi.html 2020-01-20T19:53:02.334Z https://www.astrazeneca.ca/en/media/press-releases/2020/astrazeneca-donates-over--75-000-to-food-banks-canadas-covid-19-.html 2020-06-30T13:45:42.543Z https://www.astrazeneca.ca/en/media/press-releases/2020/brilinta-approved-in-canada-to-reduce-the-risk-of-a-first-heart-.html 2020-09-01T15:02:24.345Z https://www.astrazeneca.ca/en/media/press-releases/2020/astrazeneca-and-government-of-canada-announce-agreement-to--supp.html 2020-09-25T20:27:59.584Z https://www.astrazeneca.ca/en/media/press-releases/2020/lynparza-olaparib-receives-health-canada-approval-for-the-treatment-of-BRCA.html 2020-11-25T19:52:13.358Z https://www.astrazeneca.ca/en/media/press-releases/2021.html 2026-02-03T19:07:07.866Z https://www.astrazeneca.ca/en/media/press-releases/2021/forxiga-approved-by-health-canada-for-the-treatment-of-chronic-kidney-disease.html 2021-08-11T19:02:30.493Z https://www.astrazeneca.ca/en/media/press-releases/2021/astrazeneca-canada-files-for-health-canada-authorization-of-azd7.html 2021-11-03T12:53:05.623Z https://www.astrazeneca.ca/en/media/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-ri.html 2021-11-18T13:47:29.562Z https://www.astrazeneca.ca/en/media/press-releases/2021/astrazeneca-canada-named-a-greater-toronto-top-employer-for-eigh.html 2021-12-03T14:31:12.625Z https://www.astrazeneca.ca/en/media/press-releases/2022.html 2026-02-03T19:07:19.385Z https://www.astrazeneca.ca/en/media/press-releases/2022/astrazeneca-to-supply-canada-with-100-000-doses-of-evusheld--a-l.html 2022-02-23T19:59:45.241Z https://www.astrazeneca.ca/en/media/press-releases/2022/evusheld--receives-health-canada-approval-for-pre-exposure-proph.html 2022-04-14T12:57:34.015Z https://www.astrazeneca.ca/en/media/press-releases/2022/health-canada-expands-approval-of-enhertu--for-adults-with-her2-.html 2022-06-23T13:11:00.184Z https://www.astrazeneca.ca/en/media/press-releases/2022/lynparza-receives-health-canada-approval-as-adjuvant-treatment-f.html 2024-02-08T18:19:48.129Z https://www.astrazeneca.ca/en/media/press-releases/2022/astrazeneca-canada-wins-two-prestigious-canadian-hr-awards.html 2022-09-28T13:31:02.559Z https://www.astrazeneca.ca/en/media/press-releases/2022/evusheld--receives-health-canada-approval-for-treatment-of-covid.html 2022-10-19T20:25:02.516Z https://www.astrazeneca.ca/en/media/press-releases/2022/breztri--aerosphere--now-available-in-canada-for-long-term-maint.html 2022-10-24T13:14:37.292Z https://www.astrazeneca.ca/en/media/press-releases/2022/tezspire---tezepelumab-injection--now-available-in-canada-for-se.html 2022-10-26T13:13:40.652Z https://www.astrazeneca.ca/en/media/press-releases/2023.html 2026-02-03T19:07:30.629Z https://www.astrazeneca.ca/en/media/press-releases/2023/health-canada-expands-approval-of-enhertutm-for-adults-with-her2-positive-metastatic-breast-cancer.html 2023-03-15T20:06:19.693Z https://www.astrazeneca.ca/en/media/press-releases/2023/astrazeneca-announces-major-investment-in-ontario-life-sciences-sector.html 2023-03-09T18:05:15.745Z https://www.astrazeneca.ca/en/media/press-releases/2023/health-canada-expands-approval-of-enhertutm-for-adults-with-her2-positive-metastatic-breast-cancer1.html 2023-07-19T12:03:04.120Z https://www.astrazeneca.ca/en/media/press-releases/2023/astrazeneca-canada-named-one-of-canada-s-top-employers.html 2023-11-17T17:43:00.041Z https://www.astrazeneca.ca/en/media/press-releases/2023/astrazeneca-canada-named-once-again-one-of-canada-s-most-admired.html 2023-11-23T15:47:29.784Z https://www.astrazeneca.ca/en/media/press-releases/2023/astrazeneca-canada-selected-as-a-greater-toronto-top-employer-fo.html 2024-02-08T18:14:43.652Z https://www.astrazeneca.ca/en/media/press-releases/2024.html 2026-02-03T19:07:42.926Z https://www.astrazeneca.ca/en/media/press-releases/2024/gaby-bourbara-appointed-president-of-astrazeneca-canada.html 2026-02-03T19:44:27.194Z https://www.astrazeneca.ca/en/media/press-releases/2024/astrazeneca-canada-and-plan-international-canada-announce-search.html 2026-02-03T19:44:12.111Z https://www.astrazeneca.ca/en/media/press-releases/2024/truqap---capivasertib--plus-fulvestrant-now-available-in-canada.html 2026-02-03T19:43:57.699Z https://www.astrazeneca.ca/en/media/press-releases/2024/astrazeneca-canada-and-plan-international-canada-announce-13-ins.html 2026-02-03T19:43:39.805Z https://www.astrazeneca.ca/en/media/press-releases/2024/health-canada-approves-tagrisso--with-the-addition-of-chemothera.html 2026-02-03T19:43:26.407Z https://www.astrazeneca.ca/en/media/press-releases/2024/voydeya-approved-in-canada-as-add-on-therapy-to-ravulizumab-or-e.html 2026-02-03T19:43:07.287Z https://www.astrazeneca.ca/en/media/press-releases/2025.html 2026-02-03T19:07:54.536Z https://www.astrazeneca.ca/en/media/press-releases/2025/astrazeneca-plans-c-820-million--us-570m--investment-in-canada-t.html 2026-02-03T19:39:44.405Z https://www.astrazeneca.ca/en/media/press-releases/2025/astrazeneca-canada-and-plan-international-canada-seek-next-gener.html 2026-02-03T19:40:02.540Z https://www.astrazeneca.ca/en/media/press-releases/2025/health-canada-approves-calquence--with-the-addition-of-chemoimmu.html 2026-02-03T19:42:07.623Z https://www.astrazeneca.ca/en/media/press-releases/2025/astrazeneca-canada-and-plan-international-canada-announce-10-you.html 2026-02-03T19:40:23.278Z https://www.astrazeneca.ca/en/media/press-releases/2025/health-canada-approves-fasenra---benralizumab-injection--as-an-a.html 2026-02-03T19:40:50.710Z https://www.astrazeneca.ca/en/media/press-releases/2025/health-canada-authorizes-fixed-duration-calquence--in-combinatio.html 2026-02-03T19:41:13.569Z https://www.astrazeneca.ca/en/media/press-releases/2025/enhertu--approved-in-canada-as-the-first-and-only-her2-directed-.html 2026-02-03T19:41:29.395Z https://www.astrazeneca.ca/en/media/press-releases/2025/astrazeneca-canada---the-leukemia---lymphoma-society-of-canada-a.html 2026-02-03T19:41:48.607Z https://www.astrazeneca.ca/en/media/press-releases/2026.html 2026-02-03T19:08:05.651Z https://www.astrazeneca.ca/en/media/press-releases/2026/astrazeneca-s-tagrisso--and-calquence--among-first-oncology-trea.html 2026-02-03T19:38:52.499Z https://www.astrazeneca.ca/en/media/press-releases/2026/saphnelo--subcutaneous-approved-in-canada-for-the-treatment-of-s.html 2026-04-13T11:06:47Z https://www.astrazeneca.ca/en/media/articles.html 2026-02-03T19:03:01.201Z https://www.astrazeneca.ca/en/media/articles/2020.html 2020-04-01T17:27:16.834Z https://www.astrazeneca.ca/en/media/articles/2020/covid-19--how-astrazeneca-canada-is-responding.html 2022-02-23T16:39:42.046Z https://www.astrazeneca.ca/en/media/articles/2020/astrazeneca-canada-update-on-covid-19.html 2021-03-02T21:11:11.991Z https://www.astrazeneca.ca/en/media/articles/2020/astrazeneca-canada-donation-of-200k-face-masks.html 2020-04-20T15:16:17.248Z https://www.astrazeneca.ca/en/media/articles1.html 2026-02-03T19:02:46.983Z https://www.astrazeneca.ca/en/media/social-media-community-guidelines.html 2026-02-03T19:02:32.341Z https://www.astrazeneca.ca/en/working-at-az-canada.html 2016-10-17T16:17:47.088Z https://www.astrazeneca.ca/en/working-at-az-canada/Total-Rewards.html 2025-03-14T14:31:45.775Z https://www.astrazeneca.ca/en/working-at-az-canada/astrazeneca-canada-coffee-chat-videos.html 2020-07-22T18:37:57.490Z https://www.astrazeneca.ca/en/search-jobs.html 2016-10-17T16:17:54.900Z https://www.astrazeneca.ca/en/search-jobs/Current-Positions.html 2025-02-18T15:19:12.307Z https://www.astrazeneca.ca/en/legal-notice.html 2026-02-03T18:52:08.691Z https://www.astrazeneca.ca/en/sitemap.html 2026-02-03T18:52:40.901Z https://www.astrazeneca.ca/en/astrazeneca-in-canada.html 2026-02-03T18:53:00.605Z https://www.astrazeneca.ca/en/astrazeneca-in-canada/contact-us.html 2024-06-06T17:51:41.350Z https://www.astrazeneca.ca/en/astrazeneca-in-canada/az-in-canada.html 2016-10-13T17:42:55.248Z https://www.astrazeneca.ca/en/astrazeneca-in-canada/executive-team.html 2026-07-14T14:00:13.394Z https://www.astrazeneca.ca/en/accessibility.html 2026-02-03T18:53:22.235Z https://www.astrazeneca.ca/en/patient-support-information.html 2026-01-22T12:40:51.006Z https://www.astrazeneca.ca/en/patient-choice-program.html 2024-06-06T17:14:21.370Z https://www.astrazeneca.ca/en/CookieMessageCanada.html 2019-07-25T14:51:18.894Z https://www.astrazeneca.ca/en/cookie-notice.html 2026-01-27T16:39:39.399Z https://www.astrazeneca.ca/en/impact-in-canada.html 2026-06-23T11:48:03.468Z